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Background: Ataxia Teleangiectasia [AT] is a rare neurodegenerative disease characterized by early onset ataxia,
oculocutaneous teleangiectasias, immunodeficiency, recurrent infections, radiosensitivity and proneness to cancer.
No therapies are available for this devastating disease. Recent observational studies in few patients showed
beneficial effects of short term treatment with betamethasone. To avoid the characteristic side effects of long-term
administration of steroids we developed a method for encapsulation of dexamethasone sodium phosphate (DSP)
into autologous erythrocytes (EryDex) allowing slow release of dexamethasone for up to one month after dosing.
Aims of the study were: the assessment of the effect of EryDex in improving neurological symptoms and adaptive
behaviour of AT patients; the safety and tolerability of the therapy.
Methods: Twenty two patients (F:M = 1; mean age 11.2 ± 3.5) with a confirmed diagnosis of AT and a preserved or
partially supported gait were enrolled for the study. The subjects underwent for six months a monthly infusion of
EryDex. Ataxia was assessed by the International Cooperative Ataxia Rating Scale (ICARS) and the adaptive behavior
by Vineland Adaptive Behavior Scales (VABS). Clinical evaluations were performed at baseline and 1, 3, and 6
months.
Results: An improvement in ICARS (reduction of the score) was detected in the intention-to-treat (ITT) population
(n = 22; p = 0.02) as well as in patients completing the study (per protocol PP) (n = 18; p = 0.01), with a mean
reduction of 4 points (ITT) or 5.2 points (PP). When compared to baseline, a significant improvement were also
found in VABS (increase of the score) (p < 0.0001, ITT, RMANOVA), with statistically significant increases at 3 and
6 months (p < 0.0001). A large inter-patient variability in the incorporation of DSP into erythrocytes was observed,
with an evident positive effect of higher infusion dose on ICARS score decline. Moreover a more marked improvement
was found in less neurologically impaired patients. Finally, a 19 month-extension study involving a subgroup of patients
suggested that Erydex treatment can possibly delay the natural progression of the disease.
EryDex was well tolerated; the most frequent side effects were common AT pathologies.
Conclusions: EryDex treatment led to a significant improvement in neurological symptoms, without association with
the typical steroid side effects.
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Ataxia Teleangiectasia (AT) is a rare genetic disease [1,2]
caused by biallelic mutations in the ataxia telangiectasia
mutated (ATM) gene, most of which are truncations.
The ATM gene encodes a PI3kinase, ATM, which plays
a pivotal role in the control of cell cycle and DNA repair,
targeting hundreds of substrates [3]. Homozygosity or
compound heterozygosity for ATM mutations result in a
multisystemic disorder, mainly involving nervous and
immune system. AT patients with the classical pheno-
type present with early onset ataxia, oculocutaneous
teleangiectasias, immunodeficiency, recurrent sinopul-
monary infections, radiosensitivity, proneness to cancer
and various neurodegenerative features. At cellular level
a dramatic increase in spontaneous and radiation-
induced chromosomal breaks is noticed. Neurologic
features of AT include ataxia of the trunk and limbs,
generally detected in the first years of life, progressive
supranuclear ophthalmoplegia, dysarthria, swallowing in-
coordination, facial hypomimia and delayed peripheral
neuropathy. Movement disorders such as dystonic pos-
tures and choreoathetosis could also be present and in
some cases prevalent. In the classical form, patients are
wheel-chair dependent by the age of ten [4], and their
life expectancy is around twenty-five years [5].
Anecdotal reports and a few observational short term
studies [6-9] suggested that betamethasone may be ef-
fective in improving neurological functions in AT pa-
tients. These observations were then supported by the
results of a trial in which the patients assumed for a
short-term oral betamethasone 0.1 mg/kg [10]. Most of
the patients showed a clinical response, but side effects
linked to the steroid use were observed.
A novel methodology for long-term delivery of
low doses of steroids, based on the infusion of autolo-
gous erythrocytes loaded with dexamethasone sodium
phosphate (DSP), has been developed [11]. Among
corticosteroids dexamethasone is the most similar to beta-
methasone and its high anti-inflammatory potency, to-
gether with its lack of mineralcorticoid activity, make it a
good choice for low-dose/long-term treatment as needed
in chronic inflammatory diseases. DSP incorporated into
erythrocytes is slowly converted by resident phos-
phatases to dexamethasone which is then released
into the blood stream for about twenty-thirty days or
longer.
Based on this evidence a multicenter, single-arm,
open-label Phase II clinical trial was conducted in AT
patients. The aim of the study was to evaluate the effect
of DSP encapsulated into human autologous erythro-
cytes (EryDex), given as monthly infusions over a
6-month period, in improving neurological symptoms.
Secondary objectives included the adaptive behaviour as-
sessment and the safety and tolerability evaluations.Methods
Patient population
A single-arm, open-label, 6-month Phase II study was per-
formed to assess the effect of EryDex (dexamethasone so-
dium phosphate encapsulated in autologous erythrocytes;
property of EryDel S.p.A., www.erydel.com) on neurological
symptoms of AT patients enrolled in two centers in Italy
(Department of Pediatrics and Child Neurology and Psy-
chiatry, Sapienza University, Roma, and Department of
Pediatrics, Brescia; under coordination of L.C.). Enrolling
criteria included: age 3 years or older, classical AT pheno-
type (ataxic gait, oculomotor impairment, dysarthria,
extrapyramidal disorders) with a preserved autonomous
or partially supported gait; blood CD4+ lymphocytes
counts/mm3 of ≥500 for patients aged 3–6 years or ≥200 for
patients older than 6 years; weight over 15 kg; and proven
molecular diagnosis of AT based on ATM gene mutations
and/or ATM protein deficiency. Patients were excluded
from the study on the basis of a history of severe impair-
ment of the immunological system, current or previous
neoplastic disease, chronic conditions representing a contra-
indication to the use of steroids, any serious concomitant
systemic disorders that in the opinion of the Investigator
would place the patient at excessive or unacceptable risk of
toxicity, and any previous steroid use within 30 days before
starting dexamethasone administration. The study was ap-
proved by the Ethics Committee of the involved clinical
centers and all patients provided informed consent (along
with consent of their parents or legal guardian, as required).
Assessments
The primary objective of the trial was to evaluate the effect
of EryDex in improving neurological symptoms of AT
patients over a 6-month treatment period; this was
assessed using the International Cooperative Ataxia Rating
Scale (ICARS) [12-14]. The ICARS is a 100-point semi-
quantitative scale including 19 items grouped into 4
multi-item subscales: Posture and Gait Disturbances
(maximum score =34), Kinetic Functions (maximum
score = 52), Speech Disorders (maximum score = 8), and
Oculomotor Disorders (maximum score = 6). The ICARS
rating was independently performed by 2 trained neuro-
logists in each centre (VL and DD in Roma; RM and MA
in Brescia) at baseline (before the first dose) and at 1, 3
and 6 months. Each evaluation was videotaped. Patient’s
videotapes of each centre were independently and blindly
reassessed by the neurologists of the other centre. The
final score used for the statistical analysis remained that
initially assigned by the centre-specific neurologists, due
to the overall concordance among the different examiners.
Adaptive abilities were assessed through Vineland Adap-
tive Behavior Scales (VABS), which was completed by the
patients’ parents and explores strength and weakness of
the patient in specific areas of adaptive behavior [15,16].
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of the occurrence of treatment-emergent adverse events
(TEAEs), including steroid-dependent adverse reactions
and serious AEs (SAEs); on results from standard labora-
tory tests, physical examination, vital signs, ECGs; and
on the need for concomitant medications and proce-
dures. The following additional laboratory parameters
were assessed: cholesterol (total, HDL, and LDL), glyco-
sylated hemoglobin (HbA1c), CD4+ lymphocytes count,
α–fetoprotein, and blood and urinary cortisol.
Study design
The study consisted of a Screening Period (maximum
duration 30 days), during which any possible prior
corticosteroid treatment was withdrawn, followed by a
6-month Treatment Period (Figure 1). Screening assess-
ments included medical history and demographics, phys-
ical and neurological examinations, vital signs, ECG and
standard laboratory tests. Patients meeting all the selec-
tion criteria were enrolled in the treatment period and
had the physical examination, vital signs and laboratory
tests repeated, and all efficacy evaluations performed, at
baseline (Day 0; Visit [V] 1) prior to receiving the first of
6 monthly (every 30 ± 10 days) infusions of EryDex.
The experimental treatment was prepared by collec-
ting 50 ml of peripheral blood from the patient into a
syringe containing heparin. Erythrocytes were loaded
with DSP (2 vials of 250 mg DSP/10 ml added) using the
EryDex System (www.erydel.com). The drug was en-
trapped and the cells resealed with the use of a “Red Cell
Loader” device [11]. DSP-loaded red blood cells were
then re-infused into the patient.
At each monthly visit physical examination, vital signs
and routine laboratory tests were performed. The pri-





















Figure 1 Study design.month (V2); at the 3-month visit (V4) all efficacy assess-
ments and the additional laboratory tests were per-
formed before drug infusion. A final evaluation (V7),
which included all efficacy and safety assessments, was
done at 6 months after the initial infusion (one month
after the last dose). The occurrence of any adverse event
and the use of concomitant medication were recorded
from the time of signing the consent form until the end
of the study. An evaluation of the pharmacokinetic (PK)
profile of EryDex was planned, with blood samples for
PK analysis collected from three selected patients prior
to dosing (0 hour), and 15 and 30 days post-dose at the
first and fourth infusions.
Statistical analyses
Primary endpoint
The primary analysis on ICARS was conducted on the
intention-to-treat (ITT) population. A secondary ana-
lysis on ICARS was conducted on the Per Protocol (PP)
Population. All secondary endpoints were analyzed both
on the ITT and PP populations. The safety analysis was
conducted on the Safety Population (SP). Changes at V2,
V4 and V7 vs. V1 were analyzed with a Repeated Mea-
sures Analysis of Variance (RMANOVA) with possible
covariates (among which were age and ICARS at base-
line). Wilcoxon non-parametric tests between visits were
also performed since overall analysis was significant, in
order to help determine timing. A two-tailed α-level of
0.05 was considered statistically significant.
Secondary endpoints
VABS The scores were aggregated and for each of the
four scales and each of the eleven subscales RMANOVA
(or Friedman as appropriate) was performed.led (ITT) 18 completed
-outs (PP)
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Clinically significant changes of laboratory tests and vital
signs have been summarized in shift-tables; the other
safety endpoints were reported descriptively.
Special laboratory parameters
For each of the special laboratory parameters measured
at V1, V4 and V7 absolute values and changes with re-
spect to baseline were descriptively reported. A RMA-
NOVA analysis with covariates was conducted on the
absolute values, followed if significant by paired t-tests
between visits.
Post-Hoc analyses (PP population)
A wide interindividual variation in concentrations of en-
capsulated dexamethasone in erythrocytes as well a wide
individual change in final ICARS scores became evident
after the conclusion of the study. Therefore, the ensuing
supplementary analyses aimed to explore the relation-
ship between the degree of clinical improvement and the
efficiency of dexamethasone loading in erythrocyte was
performed. Each patient was clustered according to: i) a
arbitrary cutoff value of −10 point decrement in total
ICARS scores at V7 relative to the baseline value (≥ -10
responders; ≤ -9 non-responders); and ii) a arbitrary cut-
off of 5 mg/bag, as a measure of effective erythrocyte
loading (≥5 loaders; ≤ 4.9 poor-loaders). Fisher’s exact
test was used to detect significant difference among sub
groups. A two-tailed α-level of 0.05 was considered sta-
tistically significant.
Finally the maximally sensitive ICARS subtotals were
considered.
At the end of the trial 4 subjects (cases 02.05, 02.02,
02.08, and 02.01 in Additional file 1: Table S1; mean age
12.5 years; range 11–16.6) required and were authorized
to continue Erydex treatment. So far they have been
treated for an adjunctive 19-month period. The varia-
tions of ICARS score recorded in these patients during
this extension study were compared with those detected
in 4 AT patients matched for the ICARS score at the be-
ginning of this extended study (cases 01.02, 01.07, 01.10,
and 01.11 in Additional file 1: Table S1; mean age
14.4 years; range 10–21), who had discontinued the
treatment as initially scheduled by the study design.
Results
Disposition
A total of 26 AT patients were screened and 22 were en-
rolled in the trial. Four AT patients had residual ATM
protein amounts (10% to 50% of normal). The kinase as-
says (presence/absence of autophosphorylation of ATM
in Serine1984 and phosphorylation of p53 in Serine15)
demonstrated absence of kinase activity in these sub-
jects. Thescreening failures were due to concomitantdisease (one patient) and CD4+ lymphocytes count
below the protocol cut-off (three patients). Of the 22 pa-
tients enrolled (Additional file 1: Table S1, ITT popula-
tion), 16 received the six planned infusions of EryDex; 2
patients received five infusions completing the study
(Per Protocol population) (Additional file 2: Table S2); 4
patients discontinued prematurely: one for withdrawal of
consent, one for a protocol violation (CD4+ lymphocytes
count below cut-off at baseline), and 2 for decrease in
CD4+ lymphocytes count (Additional file 3: Figure S1).
Two patients were on inhalational steroids at screening,
and these medications were discontinued one month be-
fore starting the treatment.
Demographics and Disease Characteristics of the ITT
population at V1 (Additional file 1: Table S1).
The mean age of the AT patients was 11.2 (±3.5) years,
with half (11 of 22) of the patients being males. All pa-
tients were Caucasian with a mean weight of 29.1 (±9.5)
kg and BMI of 15.6 (±2.6). The average age of diagnosis
of AT was 60.0 (±35.2) months, with a mean age of dis-
ease onset at 25.9 (±17.5) months. The mean baseline
total scores for the ICARS and VABS were 50.6 (±12.8)
and 5.5 (±2.0), respectively (Table 1 and Table 2). Mean
baseline scores on the sub-scales of ICARS were as
follows: posture/gait disturbance 20.9 (±7.1); kinetic
functions 23.1 (±6.2); speech disorders 3.5 (±1.4); and
oculomotor disorders 3.2 (±1.0).
Efficacy results
Results for the primary efficacy measure (change in total
ICARS score) for the ITT population (n = 22) indicated
an overall statistically significant (p = 0.02, RMANOVA)
improvement from baseline with EryDex treatment. The
average4-point decline in the total ICARS score ob-
served at 6 months (V7), compared to baseline, was sta-
tistically significant (p = 0.024, Wilcoxon non-parametric
test) (Table 1). An analysis performed on the Per Proto-
col population (n = 18) showed similar results, with
statistically significant improvements at 3 and 6 months
(p = 0.032 and p = 0.010, respectively) (Table 3). Once re-
stricted the analysis to the 4 patients with lowest basal
ICARS score (42 ± 1) (Additional file 2: Table S2), the
mean improvement they experienced was −12.75points
(see video recording included as Additional file 4). In
the analysis of the individual ICARS sub-scales, the
greatest overall improvement was seen in the “Kinetic
Functions” sub-scale (p = 0.0017, RMANOVA), with a
statistically significant decrease in the score at 3 (V4)
and 6 (V7) months (p = 0.027 and p = 0.003, respectively;
ITT) (Table 4).
Significant improvements were noted in adaptive be-
havior, as assessed by the VABS total score (p < 0.0001,
ITT, RMANOVA), with statistically significant increases
at 3 and 6 months (p < 0.0001), compared to baseline
Table 1 Mean ICARS Total Score and Changes from Baseline (V1) by Visit (ITT Population)
ICARS total score 95% CI for the mean MeanΔ (SD) 95% CI for meanΔ Median Min-max p-value*
V1 50.6 (12.8) (45.2/56) - 52.5 8–72 -
V2 48.4 (11.4) (43.6/53.2) −2.2 (5.6) (−4.6/0.2) 48.5 14–68 0.107
V4 47.4 (11.5) (44/51.8) −3.4 (7.3) (−6.7/0.1) 49.0 14–62 0.054
V7 46.6 (12.3) (41.4/51.8) −4.0 (7.5) (−7.1/-0.9) 48.0 14–62 0.024
*Comparison vs. baseline (V1) using Wilcoxon non-parametric test.
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Time” and “Social Rules” showed statistically significant
improvements.Pharmacokinetic profile
Due to the small amount of blood available, the samples
were pooled together and dexametasone was found to be
undetectable at pre-infusion and in the range 8–11 nM at
time 15 and 9–10 nM at time 30 days post infusion.Supplementary analyses
Data analysis revealed: a) a wide interindividual variabi-
lity in the variations of ICARS scores from basal to 7th
assessment (range −16 +9); b) a substantial variability in
the patient-specific DSP-erythrocyte loading [the mean
(SD) dose of DSP measured in all the infusion bags for
each patient ranged from 0.7 (0.1) to 18.6 (1.9) mg]
(Additional file 2: Table S2); c) a greater proportion of
loaders among females rather then males (80% vs 27%).
Statistic analysis confirmed that the efficiency of the
erythrocyte loading was related to greater improvement
(Fisher’s exact test p = 0.0090) and consequently a
greater proportion of responders among females (73%),
compared to males (18%) (Fisher’s exact test p = 0,0015).
Loaders had a mean percent decrease (improvement
relative to baseline) of −14.4% for the ICARS total score,
compared to −4.7% for “non-loaders”. Greater improve-
ment in “loaders” vs. “non-loaders” was also observed
for the ICARS Kinetic Functions sub-scale, even though
the difference did not reach statistical significance
(Fisher’s exact test p = 0.13).
A residual interindividual variability in response to
treatment could not be ascribed to any of the considered
variables as 4 out of 10 of loaders did not showed rele-
vant improvement under treatment, while ICARS score
declined of −11 points in 1 out of 10 of poor-loaders.Table 2 Mean VABS Total Score by Visit (ITT Population)
Mean (SD) 95% CI for the mean MeanΔ (SD)
V1 5.5 (2.0) (4.7/6.3) -
V4 6.5 (2.1) (6/7.8) 1.0 (0.9)
V7 6.9 (2.3) (6/8) 1.3 (1.2)
*Comparison vs. baseline (V1) using Wilcoxon non-parametric test.Finally, a mean 4.25 point-improvement (range +1 to −7)
of ICARS score was detected after 19-month extension of
Erydex treatment in subjects undergoing the extended
study, while a mean 7 point-worsening (range +1 to +14)
was found in ICARS matched controls (Additional file 5:
Table S3 and Additional file 6: Table S4).
Safety results
The Safety population included all 22 patients. Overall,
15 (68.2%) of patients experienced a total of 29 TEAEs,
most of which were rated as mild (60% of patients) and
not related to the study medication (>90% of patients).
The most common TEAEs, occurring in 10% of patients,
were cough, fever, flu syndrome and otitis, each occur-
ring in 3 (14%) patients. Two TEAEs (pneumonia and
bronchopneumonia) occurring in one patient were rated
as severe. Two possible SAEs were reported in a 7-year
old female (bronchopneumonia) and in an 11-year old
male (bronchiectasis with bleeding), both of which re-
quired hospitalization. These events, which are common
in AT patients and had occurred in the sample as a
whole with a similar frequency as in the pre-treatment
period. were not considered to be related to the study
medication. The most frequently used concomitant me-
dications were antibacterials and analgesics.
Only one patient experienced an AE judged to be
related to the study medication, a mild increase in choles-
terol levels (from 5.17 mmol/L at baseline to 5.66 mmol/L
at final visit). Two patients had a >20% decrease in CD4+
lymphocytes count during the study period, which re-
sulted in premature discontinuation. These were not re-
ported as AEs by the Investigator, but were considered
AEs as per protocol definition and rated as mild with
unsuspected relationship to study medication.
There were no clinically meaningful changes in mean
values for routine laboratory parameters with EryDex
treatment, except for serum iron, which showed a mean95% CI for meanΔ Median Min-max p-value*
5.1 2.1–11.0 -
(0.7/1.5) 6.2 3.6–10.9 <0.0001
(0.8/1.8) 6.9 2.5–11.1 <0.0001
Table 3 Mean ICARS Total Score by Visit (PP Population)
Mean (SD) MeanΔ (SD) Median Min-max p-value*
V1 51.8 (7.7) - 52.5 37–68 -
V2 49.4 (8.5) −2.4 (4.9) 48.5 36–68 0.059
V4 47.9 (9.0) −3.9 (7.1) 49.0 30–61 0.032
V7 46.7 (10.1) −5.2 (7.0) 46.0 26–61 0.010
*Comparison vs. baseline (V1) using Wilcoxon non-parametric test.
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with 8 patients having newly occurring abnormal low
values at the final visit (one reported as a TEAE)
(Additional file 7: Table S5). For the special laboratory
parameters, no clinically meaningful changes were ob-
served, except for urinary cortisol, which showed an ap-
proximately 26.3% decrease from baseline to the final
visit (p = 0.016). Although this could indicate an effect of
EryDex on the hypothalamo-pituitary-adrenal axis, a com-
parison of blood and urinary cortisol levels vs. dose did
not indicate any relationship. No clinically significant
changes with EryDex treatment were observed for vital
signs, ECGs, or physical examination findings. No signifi-
cant changes in blood pressure were detected in any pa-
tient during the entire trial (Additional file 8: Table S6).
Discussion
In this open-label study involving AT patients aged more
than 3 years the EryDex treatment for 6 months led to a
significant improvement in ICARS, the primary efficacy
measure which assesses the key symptoms of the disease.
Significant benefits of EryDex treatment were more rele-
vant in the Kinetic Functions sub-scale of the ICARS
and in measures assessing the patients’ adaptive behavior
(VABS).
A limiting issue in all the trials focusing on AT is the
lack of a dedicated rating scales to assess the complex
neurologic impairment in this disease and the variable
contribution of different movement disorders to the
morbidity of the patients. Waiting for an ad hoc scale
for A-T, which is being currently validated [17], ICARS
remains the most extensively used scale for children
with ataxia. It is characterized by a good inter-rater reli-
ability and it is designed for ataxic symptoms regardless
of etiology [12]. Focusing on AT, main constraints of the
scale are: the lack of a scoring subscale for dyskineticTable 4 Mean ICARS Kinetic Functions Subscale Score by Visit
Mean (SD) 95% CI for the mean MeanΔ (SD)
V1 23.1 (6.2) (20.5/25.7) -
V2 22.0 (5.0) (19.9/24.1) −1.1 (3.3)
V4 20.6 (5.2) (19/22.6) −2.5 (4.7)
V7 20.2 (5.1) (18.1/22.3) −2.9 (3.8)
*Comparison vs. baseline (V1) using Wilcoxon non-parametric test.movements (such as chorea, dystonia, athetosis, myoclo-
nus), which are prevalent in a low percentage of AT sub-
jects [18] and the non-tailored sub items dealing with
eye movement impairment and speech disorders. VABS
was used in our study to provide additional information
on the global functioning in term of daily living skills. In
patients with a more severe neurological impairment,
VABS score seemed to reflect better than ICARS score
the clinical improvement detected by the clinical obser-
vation. Few studies addressed the issue of therapeutic
strategies in AT patients. Nissenkorn et al. [19] demon-
strated that amantadine sulfate improves ataxia in AT
patients with a mild impairment (ICARS 38.94 ± 10.13).
Recently, Zannolli et al. [10] performed a multicenter
double-blind randomized short term (30 days) trial with
betamethasone vs placebo in AT patients with a mode-
rate neurological impairment (median initial ICARS total
score 44). Even though patients under betamethasone
experienced a significant reduction of ICARS score, they
also experienced important adverse events (increases in
BMI, cholesterol, and HDL cholesterol and decrease in
blood phosphorus). In contrast, in this study EryDex
treatment was well tolerated during a six month trial
and no variations were observed in vital signs and bio-
chemistry. The most common TEAEs were moderate
and considered ‘not related’ to the study medication,
being conditions generally related to the disease.
Our results are impressive taking in consideration that
most of the patients had an advanced form of the disease
(score at baseline: 50.7 ± 12.8, range 42 to 68). When
the patients with milder neurological involvement were
considered, the improvement was more remarkable, sug-
gesting the efficacy of treatment as function of the stage
of the disease. Moreover, the clinical improvement at
ICARS scores was even more relevant in patients with
the most efficient dexamethasone loading in the erythro-
cytes. As this point is concerned, a greater proportion of
females, compared to males, had mean doses of DSP of
5 mg or more. Mean value (and SD) of DSP content in
the processed erythrocytes was 10.39 ± 6.28 in female,
and 4.79 ± 4.68 mg/bag in male patients (n = 10 and 11
respectively) and t-test showed statistical significance of
the difference between the two groups (P < 0.03). Since a
higher dose was shown to correlate with a greater re-
sponse on ICARS, the proportion of female patients(ITT Population)
95% CI for meanΔ Median Min-max p-value*
23.5 2–36 -
(−2.5/0.3) 22.0 6–32 -
(−4.6/-0.6) 21.0 6–28 0.027
(−4.5/-1.3) 20.5 6–28 0.003
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point improvement on the ICARS total score at the final
visit) was higher than for males. One finding that needs
further exploration is the low level of DSP-erythrocyte
encapsulation (almost half of the patients had mean in-
fusion bag doses of less than 5 mg of DSP) and high
level of variability in this trial, in comparison to previous
studies that used EryDex as treatment device [20-25].
This may be due to an intrinsic biochemical change in
the cell membrane of the erythrocyte in AT patients, as
previously reported [26,27]. These changes in physico-
chemical properties could influence the encapsulation of
DSP into AT patients’ erythrocytes and the consequent
release of the active drug into the circulation. Further re-
finements in the procedure for loading erythrocytes with
DSP are being made to ensure higher entrapment and
lower intra- and inter-individual variability. No effect of
age on the response to EryDex treatment was found.
This study provides support for the use of intra-
erythrocyte DSP (EryDex) in the treatment of patients
suffering AT, a so far untreatable disease. By continu-
ously providing low dose levels of dexamethasone,
EryDex should avoid the side effects of long-term steroid
use, a great result in a population of patients which need
a chronic treatment. The feasibility of a large double-
blind, placebo-controlled trial should be carefully evalu-
ated in order to confirm these preliminary findings and
to assess long-term effectiveness and safety. Looking at
future studies, we need to explore the efficacy of treat-
ment in preventing or postponing the key milestones in
the natural history of AT, so changing the disease course
as already reported for other disorders [28]. From this
point of view, as preliminary observation, the extended
study performed in 4 subjects suggests that Erydex treat-
ment could actually delay the natural progression of the
disease.
It is worth noting that in vitro dexamethasone was
shown to induce a non-canonical splicing that leads to
translation of a short ATM variant retaining kinase ac-
tivity. Thus, ATM may be restored by a new molecular
mechanism which overcomes must of the mutations so
far described in ATM gene [29]. Once confirmed in
other studies this observation will provide the molecular
basis for dexamethasone action in AT patients. Other
mechanism(s) of dexamethasone that could contribute
to the explanation of observed clinical improvement
(i.e. dexamethasone anti-inflammatory effects) should be
considered and are under investigation.
Conclusions
DSP delivered by erythrocyte is a promising treatment
strategy for long-term steroid administration in AT pa-
tients, which confirms the efficacy of the steroids in
improving the neurological deficits associated with thedisease while minimizes the side effects resulting from
the oral administration of these drugs. The potential effi-
cacy of this treatment in modifying the natural course of
AT warrants further studies.Additional files
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